Xeris Biopharma insider sells 15,000 shares at $8

Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported selling 15,000 shares of common stock at $8.00 per share on January 8, 2026.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported selling 15,000 shares of common stock at $8.00 per share on January 8, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, he beneficially owned 1,685,426 shares of common stock directly and 25,000 shares indirectly through his spouse. He serves as President and Chief Operating Officer of the company.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 2 txns

Insider McCulloch Kevin

Role See Remarks

Sold 15,000 shs ($120K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,000	$8.00	$120K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,685,426 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xeris Biopharma (XERS) report?

Xeris Biopharma reported that officer Kevin McCulloch sold 15,000 shares of common stock at $8.00 per share on January 8, 2026.

At what price were the Xeris Biopharma shares sold in this Form 4?

The reported sale involved 15,000 shares of Xeris Biopharma common stock at a price of $8.00 per share.

How many Xeris Biopharma shares does Kevin McCulloch own after the transaction?

Following the transaction, Kevin McCulloch beneficially owned 1,685,426 shares of Xeris Biopharma common stock directly and 25,000 shares indirectly through his spouse.

Was the Xeris Biopharma insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What is Kevin McCulloch’s role at Xeris Biopharma (XERS)?

According to the filing, Kevin McCulloch is the company’s President and Chief Operating Officer.

How are the spouse’s Xeris Biopharma shares treated in this Form 4?

The Form 4 reports 25,000 shares of common stock as indirectly owned "By Spouse", with a disclaimer that the reporting person only acknowledges beneficial ownership to the extent of his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:34 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S(1)		15,000	D	$8	1,685,426	D
Common Stock								25,000(2)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.